Phase 2Completed
Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)
- Sponsor
- Assistance Publique - Hôpitaux de Paris (Academic or other)
- Enrolment
- 35 enrolled
- Conditions
- Transient; Hypoglycemia, Neonatal; Preterm; Glibenclamide Adverse Reaction
- Interventions
- Glibenclamide; Pharmacokinetics study; C-peptide proinsulin ratio; Routine biological monitoring
- Ages
- children
- Registry
- NCT05687500, EUCTR2021-005766-18
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Primary outcomes
- Blood glucose control
History
Last registry update
Study completion
Primary completion
Started
Registered